Table 3.

Short- and long-term safety and efficacy outcomes.

	Dofetilide – AF (N = 21)	Sotalol – AF (N = 52)	Sotalol – VA (N = 18)	Sotalol – All (N = 61)	P-value (Dofetilide – AF vs Sotalol – AF)
Total follow-up days, median (IQR)	2630 (1569, 4420)	1272 (951, 3778)	1385 (1004, 3986)	1286 (953, 3155)	0.072
Total days on treatment, median (IQR)	563 (96, 1362)	566 (165, 1321)	190 (102, 1227)	616 (156, 1303)	0.514
HF hospitalizations at 1 year, N (%)	0 (0.0)	3 (5.8)	1 (5.6)	3 (4.9)	0.176
Cardiovascular death at 1 year, N (%)	0 (0.0)	1 (1.9)	0 (0.0)	1 (1.6)	0.495
All-cause death at 1 year, N (%)	0 (0.0)	2 (3.8)	0 (0.0)	2 (3.3)	0.356
Arrhythmia recurrence at 1 year, N (%)	9 (42.9)	23 (44.2)	9 (50.0)	31 (50.8)	0.665
Long-term arrhythmia recurrence, N (%)	15 (71.4)	38 (73.1)	13 (72.2)	51 (83.6)	0.223
Discontinued at 1 year, N (%)	8 (38.1)	15 (29.4)	8 (44.4)	18 (29.5)	0.358
Long-term discontinuation, N (%)	16 (76.2)	32 (61.5)	12 (66.7)	36 (59.0)	0.084
Reason for discontinuation, N (%)
Inefficacy	6 (28.9)	14 (26.9)	3 (16.7)	17 (27.9)
Adverse event	2 (9.5)	11 (21.2)	4 (22.2)	11 (18.0)
HF signs and symptoms	0 (0.0)	4 (7.7)	1 (5.6)	4 (6.6)
QT prolongation	2 (9.5)	3 (5.8)	1 (5.6)	3 (4.9)
Hypotension	0 (0.0)	1 (1.9)	1 (5.6)	1 (1.6)
Bradyarrhythmia	0 (0.0)	3 (5.8)	1 (5.6)	3 (4.9)
Side-effects	3 (14.3)	4 (7.7)	5 (27.8)	8 (13.1)
Fatigue, dyspnea, or weakness	1 (4.8)	2 (3.8)	3 (16.7)	4 (6.6)
Dizziness	0 (0.0)	1 (1.9)	2 (11.1)	3 (4.9)
GI intolerance	0 (0.0)	1 (1.9)	0 (0.0)	1 (1.6)
Depression	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)
Hives	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)
Other (Heart transplant, patient preference, guideline non-compliance due to LVH)	3 (14.3)	1 (1.9)	0 (0.0)	1 (1.6)

IQR inter-quartile range, HF heart failure, LVH left ventricular hypertrophy.